Ecromeximab
- Generic Name
- Ecromeximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 292819-64-8
- Unique Ingredient Identifier
- M76FX2JZRM
- Background
Ecromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 36
- Registration Number
- NCT00679289
- Locations
- 🇺🇸
University of Chicago Hospital, Chicago, Illinois, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath